Associations of plasma kynurenines with risk of acute myocardial infarction in patients with stable angina pectoris

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 35, Issue 2, 2015, Pages 455-462

  Pedersen, Eva Ringdal ^a   Tuseth, Nora ^a,b   Eussen, Simone J P M ^a,c   Ueland, Per Magne ^a,b,d   Strand, Elin ^a   Svingen, Gard Frodahl Tveitevåg ^a   Midttun, Øivind ^d   Meyer, Klaus ^d   Mellgren, Gunnar ^a,b,f   Ulvik, Arve ^d   Nordrehaug, Jan Erik ^a,e   Nilsen, Dennis W ^a,e   Nygård, Ottar ^a,b,f  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d BEVITAL AS   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f KG Jebsen Center for Diabetes Research   (Norway)

Author keywords

acute myocardial infarction; atherosclerosis; diabetes mellitus; epidemiology; inflammation; insulin resistance; tryptophan

Indexed keywords

ANTHRANILIC ACID; HYDROXYANTHRANILIC ACID; HYDROXYKYNURENINE; KYNURENIC ACID; KYNURENINE; PYRIDOXAL 5 PHOSPHATE; TRYPTOPHAN; UNCLASSIFIED DRUG; XANTHURENIC ACID; ANTHRANILIC ACID DERIVATIVE; BIOLOGICAL MARKER;

ACUTE HEART INFARCTION; ADULT; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BLOOD SAMPLING; CLASSIFICATION; CORONARY RISK; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STABLE ANGINA PECTORIS; ANGINA, STABLE; BLOOD; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; INCIDENCE; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NORWAY; PREDIABETIC STATE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; UPREGULATION;

AGED; ANGINA, STABLE; BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INCIDENCE; KYNURENINE; LINEAR MODELS; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NORWAY; ORTHO-AMINOBENZOATES; PREDIABETIC STATE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION; XANTHURENATES;

EID: 84922022406     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.114.304674     Document Type: Article

References (40)

1. Donath MY. Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat Rev Drug Discov. 2014;13:465-476. doi:10.1038/nrd4275.
2. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695. doi:10.1056/NEJMra043430.
3. McNelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. Immunity. 2014;41:36-48. doi:10.1016/j.immuni.2014.05.010.
4. Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a high-risk state for diabetes development. Lancet. 2012;379:2279-2290. doi:10.1016/S0140-6736(12)60283-9.
5. Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res. 2005;54:395-411. doi:10.1007/s00011-005-1377-2.
6. Schrcksnadel K, Wirleitner B, Winkler C, Fuchs D. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta. 2006;364:82-90. doi:10.1016/j.cca.2005.06.013.
7. Fuchs D, Avanzas P, Arroyo-Espliguero R, Jenny M, Consuegra-Sanchez L, Kaski JC. The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem. 2009;16:4644-4653.
8. Pedersen ER, Midttun Oø, Ueland PM, Schartum-Hansen H, Seifert R, Igland J, Nordrehaug JE, Ebbing M, Svingen G, Bleie Oø, Berge R, Nygård O. Systemic markers of interferon-γ-mediated immune activation and long-term prognosis in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2011;31:698-704. doi: 10.1161/ATVBAHA.110.219329.
9. Sulo G, Vollset SE, Nygård O, Midttun Oø, Ueland PM, Eussen SJ, Pedersen ER, Tell GS. Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study. Int J Cardiol. 2013;168:1435-1440. doi:10.1016/j.ijcard.2012.12.090.
10. Pedersen ER, Svingen GF, Schartum-Hansen H, Ueland PM, Ebbing M, Nordrehaug JE, Igland J, Seifert R, Nilsen RM, Nygård O. Urinary excretion of kynurenine and tryptophan, cardiovascular events, and mortality after elective coronary angiography. Eur Heart J. 2013;34:2689-2696. doi:10.1093/eurheartj/eht264.
11. Niinisalo P, Oksala N, Levula M, Pelto-Huikko M, Järvinen O, Salenius JP, Kytmäki L, Soini JT, Kähnen M, Laaksonen R, Hurme M, Lehtimäki T. Activation of indoleamine 2,3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere vascular study. Ann Med. 2010;42:55-63. doi:10.3109/07853890903321559.
12. Oxenkrug G. Insulin resistance and dysregulation of tryptophan-kynurenine and kynurenine-nicotinamide adenine dinucleotide metabolic pathways. Mol Neurobiol. 2013;48:294-301. doi:10.1007/s12035-013-8497-4.
13. Pertovaara M, Raitala A, Juonala M, Lehtimäki T, Huhtala H, Oja SS, Jokinen E, Viikari JS, Raitakari OT, Hurme M. Indoleamine 2,3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: the Cardiovascular Risk in Young Finns Study. Clin Exp Immunol. 2007;148:106-111. doi:10.1111/j.1365-2249.2007.03325.x.
14. Theofylaktopoulou D, Midttun O, Ulvik A, Ueland PM, Tell GS, Vollset SE, Nygård O, Eussen SJ. A community-based study on determinants of circulating markers of cellular immune activation and kynurenines: the Hordaland Health Study. Clin Exp Immunol. 2013;173:121-130. doi:10.1111/cei.12092.
15. Pawlak K, Mys̈liwiec M, Pawlak D. Kynurenine pathway -a new link between endothelial dysfunction and carotid atherosclerosis in chronic kidney disease patients. Adv Med Sci. 2010;55:196-203. doi:10.2478/ v10039-010-0015-6.
16. Pawlak K, Mysliwiec M, Pawlak D. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients. Thromb Res. 2010;125:e40-e45. doi:10.1016/j. thromres.2009.08.009.
17. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation. 2012;125:2222-2231. doi:10.1161/CIRCULATIONAHA.111.067827.
18. Wolowczuk I, Hennart B, Leloire A, Bessede A, Soichot M, Taront S, Caiazzo R, Raverdy V, Pigeyre M, Guillemin GJ, Allorge D, Pattou F, Froguel P, Poulain-Godefroy O; ABOS Consortium. Tryptophan metabolism activation by indoleamine 2,3-dioxygenase in adipose tissue of obese women: an attempt to maintain immune homeostasis and vascular tone. Am J Physiol Regul Integr Comp Physiol. 2012;303:R135-R143. doi:10.1152/ajpregu.00373.2011.
19. Moffett JR, Namboodiri MA. Tryptophan and the immune response. Immunol Cell Biol. 2003;81:247-265. doi:10.1046/j.1440-1711.2003. t01-1-01177.x.
20. Zhang L, Ovchinnikova O, Jönsson A, Lundberg AM, Berg M, Hansson GK, Ketelhuth DF. The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice. Eur Heart J. 2012;33:2025-2034. doi:10.1093/eurheartj/ ehs175.
21. Sallée M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins (Basel). 2014;6:934-949. doi:10.3390/ toxins6030934.
22. Saito K, Fujigaki S, Heyes MP, Shibata K, Takemura M, Fujii H, Wada H, Noma A, Seishima M. Mechanism of increases in L-kynurenine and quinolinic acid in renal insufficiency. Am J Physiol Renal Physiol. 2000;279:F565-F572.
23. Pawlak D, Tankiewicz A, Matys T, Buczko W. Peripheral distribution of kynurenine metabolites and activity of kynurenine pathway enzymes in renal failure. J Physiol Pharmacol. 2003;54:175-189.
24. van der Kloet FM, Tempels FW, Ismail N, et al. Discovery of earlystage biomarkers for diabetic kidney disease using ms-based metabolomics (FinnDiane study). Metabolomics. 2012;8:109-119. doi:10.1007/ s11306-011-0291-6.
25. Stone TW, Darlington LG. Endogenous kynurenines as targets for drug discovery and development. Nat Rev Drug Discov. 2002;1:609-620. doi:10.1038/nrd870.
26. Polovina MM, Potpara TS. Endothelial dysfunction in metabolic and vascular disorders. Postgrad Med. 2014;126:38-53. doi:10.3810/ pgm.2014.03.2739.
27. Rochette L, Lorin J, Zeller M, Guilland JC, Lorgis L, Cottin Y, Vergely C. Nitric oxide synthase inhibition and oxidative stress in cardiovascular diseases: possible therapeutic targets? Pharmacol Ther. 2013;140:239-257. doi:10.1016/j.pharmthera.2013.07.004.
28. Sekkaï D, Guittet O, Lemaire G, Tenu JP, Lepoivre M. Inhibition of nitric oxide synthase expression and activity in macrophages by 3-hydroxyanthranilic acid, a tryptophan metabolite. Arch Biochem Biophys. 1997;340:117-123.
29. Fujigaki H, Saito K, Lin F, Fujigaki S, Takahashi K, Martin BM, Chen CY, Masuda J, Kowalak J, Takikawa O, Seishima M, Markey SP. Nitration and inactivation of IDO by peroxynitrite. J Immunol. 2006;176:372-379.
30. Wang Y, Liu H, McKenzie G, et al. Kynurenine is an endothelium-derived relaxing factor produced during inflammation. Nat Med. 2010;16:279-285. doi:10.1038/nm.2092.
31. Bardgett ME, McCarthy JJ, Stocker SD. Glutamatergic receptor activation in the rostral ventrolateral medulla mediates the sympathoexcitatory response to hyperinsulinemia. Hypertension. 2010;55:284-290. doi:10.1161/HYPERTENSIONAHA.109.146605.
32. Würtz P, Soininen P, Kangas AJ, Rönnemaa T, Lehtimäki T, Kähönen M, Viikari JS, Raitakari OT, Ala-Korpela M. Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults. Diabetes Care. 2013;36:648-655. doi:10.2337/dc12-0895.
33. Adams SH. Emerging perspectives on essential amino acid metabolism in obesity and the insulin-resistant state. Adv Nutr. 2011;2:445-456. doi:10.3945/an.111.000737.
34. Cutler JA, Rush AJ, McMahon FJ, Laje G. Common genetic variation in the indoleamine-2,3-dioxygenase genes and antidepressant treatment outcome in major depressive disorder. J Psychopharmacol. 2012;26:360-367. doi:10.1177/0269881111434622.
35. de Souza FR, Fontes FL, da Silva TA, Coutinho LG, Leib SL, Agnez-Lima LF. Association of kynurenine aminotransferase II gene C401T polymorphism with immune response in patients with meningitis. BMC Med Genet. 2011;12:51. doi:10.1186/1471-2350-12-51.
36. Agudelo LZ, Femenía T, Orhan F, et al. Skeletal muscle PGC-1α1 modulates kynurenine metabolism and mediates resilience to stress-induced depression. Cell. 2014;159:33-45. doi: 10.1016/j.cell.2014.07.051.
37. Dawson AJ, Sathyapalan T, Atkin SL, Kilpatrick ES. Biological variation of cardiovascular risk factors in patients with diabetes. Diabet Med. 2013;30:1172-1180. doi:10.1111/dme.12160.
38. Jansen H, Stolk RP, Nolte IM, Kema IP, Wolffenbuttel BH, Snieder H. Determinants of HbA1c in nondiabetic Dutch adults: genetic loci and clinical and lifestyle parameters, and their interactions in the Lifelines Cohort Study. J Intern Med. 2013;273:283-293. doi:10.1111/joim.12010.
39. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013;36(suppl 1):S67-74. doi: 10.2337/ dc13-S067.
40. Midttun O, Townsend MK, Nygård O, Tworoger SS, Brennan P, Johansson M, Ueland PM. Most blood biomarkers related to vitamin status, one-carbon metabolism, and the kynurenine pathway show adequate preanalytical stability and within-person reproducibility to allow assessment of exposure or nutritional status in healthy women and cardiovascular patients. J Nutr. 2014;144:784-790. doi: 10.3945/jn.113.189738.